Decline in hormone replacement prescription and fall in breast cancer incidence: an epidemiological discourse.
other · Level V
Where this comes from
- Record sourced from PubMed, PMID 19629226.
- Also identified by DOI 10.3238/arztebl.2008.0303 and PMC identifier PMC2360203.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
INTRODUCTION: Between 2002 and 2003 the incidence of invasive breast cancer among women aged 50 to 69 years declined considerably in the US. This decline was accompanied by a substantial fall in prescription rates of estrogen-progestin (EG-HRT). METHODS: Selective literature search in PubMed from 01/2003 to 12/2007 using the key words "hormone replacement therapy," "incidence," and "breast cancer." RESULTS: The parallel decline in EG-HRT and breast cancer suggests a causal link. Up to now, alternative explanations for the decline of the incidence can either be refuted or revealed as implausible. DISCUSSION: Detailed incidence trend analyses in the coming years and a close monitoring of EG-HRT prescription rates in and beyond the US. promise important insights. If EG-HRTs are carcinogenic, the extent of this effect remains unclear. If cessation of EG-HRT therapy only delays the appearance of detectable breast cancer, a long-term increase in incidence would be expected in women of age 50 and older, even with low prescription rates. However, if cessation of EG-HRT also stops tumor growth, the anticipated incidence will be permanently lower in the future.